Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A little indifference on a couple fronts as to why after taking over control of Inspyr Ridgeway (Hislop) did not make a change in the CEO of nspx. It appears Hislop is well ingrained in the team at Geiger so his time at Inspyr may be limited. We all know Cain is just a figure head so any action on this ticker will have to be generated by Hislop.
Rallied hard and fast in the past when news came out.. there is no reason why it won't happen again. Lots of energy waiting for a update or news concerning this ticker.
Lots of shares on the bid and mm gladly pushing shares to cover them! Many what shares in this ticker!
Could go either way.. with no support from the company the price is in the hands of the MM and they will do what they want or need to do to move shares. A substantial move is waiting in the wings for updates and/or news from the company!
price action today a bit ugly.. couldn't hold above .01.. mini rally needs something to keep the recent upswing intact. Where are you Dr. Hislop???
The same scenario happens over and over with this ticker... news comes out pps rallies with heavy volume.. no follow thru from the company.. volume and interest fades along with pps. The question is how much interest, volume and pps will it retrace until the scenario repeats itself. It will repeat and just maybe the news will be major. Trade if you want to but don't get caught without a solid position.
Been like that for awhile .. no one at home at shareholder services! I think things are set up for positive actions with the drug platforms. It may not be today or tomorrow or next week or next month but resent actions are indications of a move forward. If RT-AR001 is all it's touted to be things may move fast.
Right on.. I've expected a new hire as CEO of Inspyr ever since Ridgeway took over the control of the operations. Puzzling why it has not happened yet. NSPX hasn't had a bio man in charge since Dionne left in 2016. Last two CEOs.. Chris Lowe and Michael Cain both like fish out of water.
Yea crazy.. ticker announces its going to borrow 500k more money from the investor it just borrowed 600K a few months ago and traders are coming out of the woodwork to grab shares. Taken for a ride to .016 and back. The only positive is that in last 10-Q nspx said they had enough cash on hand to last thru 2nd quarter so why the need for cash now.. maybe moving forward with RT-AR001 at a quicker pace???
17 been around awhile and knows how fast this ticker rallies and how fast the rally fades. The retreat has left many behind. The fact you can borrow money doesn't add value to the stock. The ticker needs a 8-K that shows financial value for the drug platforms then maybe the rally will have some legs!
Seen this type day before on this ticker.. 2nd 500k influx of cash in last few months (8-K 10/29). Maybe moving forward as stated with RT-AR001.
Has held on so far in 21..somewhat encouraging. Many waiting in the wings to move the ticker forward when the time comes. Hislop, Ridgeway or Inspyr won't be quite for long!
Although it appears that Dr. Hislop and Inspyr have gone all in on the development of RT-AR001 (the novel adenosine immuno-oncology based platform) it may be short thinking that all is lost or given up on mipsagargin. Certain drugs take years to obtain the right opportunity or interest from the right parties to move forward. A drug with orphan status until 2034 and completed PH II trials with fairly positive results may show some life. 2021 should be an interesting year as Hislop gained control in late 2020 and got things in line for development of Inspyr.
I wouldn't worry too much about Dr. Hislop. He's probably busy spending that fat bonus from EIGER's 95 Million payday for pushing thru Lonafarnib to FDA approval. Also, busy putting NDA (new drug application) information to FDA for RT-AR001. He, Ridgeway and Inspyr will do just fine!
Why have there been nervous investors?
The company is now in the process of commencing corporate operations including: pre-clinical research and development, manufacturing, regulatory and business development. The company is dedicated to continuing to execute its new corporate strategy and will provide timely updates to shareholders.
It seems we have heard this before!
There has been nothing posted that Dr. Hislop is CEO of Inspyr. He is President and CEO of Ridgeway Therapeutics and thru an agreement on 10/08 Ridgeway has taken control of Inspyr. Michael Cain is still listed as CEO of Inspyr on all documents. That last PR of 12/10 did nothing but confuse all about some sort of Global plan or whatever thrown out there for what reason.. who knows?. PPS has been falling since. Until Hislop has some bonified "good" news concerning the drug platforms it's probably better to say nothing.
Yes for sure there is something here! Nspx is the ever ready bunny of pinkies. It’s been through name change, sub zero management, toxic debt structures, 3 reverse splits and been on the verge of collapse for years. Yet as 2021 approaches, with all that any positive news on the existing drug platforms the stock could advance dramatically. This is more possible than ever with Ridgeway in control of Inspyr!
Not to worry! the longer the wait the bigger the bombshell Hislop will come up with!!
Short memories have forgot about the move from.0015 to .03+ in March and from .0035 to .07+ in October. They must have some info to know that these kind of moves will never happen again.. Yeah Right! Sell now for pennies or wait it out and maybe those pennies will grow into something more valuable!
It's certain from recent activity and filings that NSPX with Colin in charge has set in motion the development of RT-AR001 as Inspyr's primary focus. However, it is difficult to comprehend (although certainly possible) that Inspyr has completely given up on Mipsagargin. With orphan status until 2034, fairly positive clinical trial results and new avenue for thapsigargin production with PHYTON and with Colin's connections you would think that some development in mipsagargin is still possible. The Ridgeway control of Inspyr has only been in effect for a few months so probably prudent to see what happens going forward.
Yes good to see any updates..after being shut out for a couple of years by the Lowe/Cain mismanagement team. Maybe NSPX will follow thru with timely updates to stakeholders as they mentioned in the article. Don't quite know what to take of the drug going global but if Hislop can find investors/partners on foreign soil..go for it. Cancer does not discriminate and has no boundaries.
There is little confidence in the stock advisors and pundits concerning this ticker. Over the years they have been almost always wrong. No one really knows where this is going especially with a new drug and capable leader in Colin Hislop.
Eiger BioPharmaceuticals Sells Priority Review Voucher for $95 Million after getting Zokinvy (Lonafarnib) FDA approved.
Can Dr. Hislop help Inspyr as he did getting Eiger Lonafarnib FDA approved?
Dr. Hislop a Heavy Hitter that has a history of getting it done!
Ha..if the target was .86 prior to 2nd after the rs the new target would be 21.5 (.86 x 25) then after the 3 rd it would be 645 (21.5 x 30) .. so we can safely say a target of .86 would be more realistic than 647. we'll see if it can get there!
Subs mean nothing to this ticket., it has rallied hard from subs before!
Man now in control of Inspyr!
Colin Hislop has over 30 years of experience in drug development including small molecules, peptides and biologics, across therapeutic areas in both large pharma and start-up companies. Prior to joining Eiger full-time, Dr. Hislop was the Company’s senior medical advisor to the Progeria program and was instrumental to Eiger’s first NDA submission of Lonafarnib for the treatment of Progeria and Progeroid Laminopathies.
Prior to joining Eiger, Dr. Hislop served as Chief Medical Officer at Versartis and Anthera. He was previously Vice President and Head of Clinical Development at Peninsula Pharmaceuticals developing doripenem for systemic infections. Peninsula was acquired by J&J for $245 million. Dr. Hislop served as Vice President of Clinical Development at CV Therapeutics where he developed and filed an NDA for Ranexa for angina. CV Therapeutics was acquired by Gilead for $1.4 billion. He previously led the development of Actonel through initial FDA approvals for osteoporosis at Proctor & Gamble. Dr. Hislop began his industry career at Eli Lilly as Medical Director of Endocrinology for insulin and growth hormone. During his career, Dr. Hislop has been involved in all phases of drug development from IND to Phase 4, and has led numerous US, European, and global regulatory filings, including 4 NDAs.
Dr. Hislop earned a Bachelor of Science in Medical Biochemistry from the University of Surrey and a Bachelor of Medicine, Bachelor of Surgery (M.B.B.S.) at the University of London.
Colin could most likely pay off most of that debt from the Xmas bonus he’ll get for making Eigers $ 47,500,000 payday happen!
In the 8-K dated 10/8 Hislop/Ridgeway commandeered and took control of Inspyr. All patents and Intellectual Property (IP) are in the their hands. Since then they have increased the AS, secured "keep the lights on" cash ($500,000) and with recent 8-K organized the outstanding convertible debt with Sabby. The 2.3 million debt is minuscule to the financial benefit that a novel oncology drug can realize. Ridgeway/Hislop/Inspyr are now all set up.. let's see how decisively Hislop moves this newly touted drug platform forward.
A little more about Dr. Hislop who is now in control of Inspyr.
Dr. Hislop was the Company’s senior medical advisor to the Progeria program and was instrumental to Eiger’s first NDA submission of Lonafarnib for the treatment of Progeria and Progeroid Laminopathies.
Eiger got FDA approval for Lonafarnib (it is Eigers only FDA approved drug) and immediately sold it for 95 million splitting the take with the Progeria Foundation. (47.5 million each).
If you are thinking that Dr. Hislop is going to sit on his hands and not advance the newly developed novel therapy RT-AR001 you may be thinking too much and possibly thinking yourself out of a substantial pay day.
New business plan: 1. Inspyr licenses adenosine platform to Ridgeway. 2. Ridgeway researches and develops novel therapy RT-AR001. 3. Ridgeway sells the rights to RT-AR001 back to Inspyr for 65 million shares, 8000 preferred shares and control of Inspyr. 4. Ridgeway and Inspyr in combination proceed to dilute and tank the pps so that the 65 million shares and all investors money is worthless. To some that is what they believe is the future scenario of NSPX, however there are many that think that Ridgeway and Colin Hislop have a completely different path coming to this ticker.
Flyerfan your better than that.. obviously a typo 9593118 is the adenosine patent they should have referred to.. RT-AR001 probably refers to Ridgeway Therapeutics-Adenosine Receptor001 as it if the first in a new class of adenosine base drugs. Cutting edge stuff so not much research info to base any information on the therapy. Skepticism on steroids!
Yes some loose ends and questions for sure! Big one is why Colin, Ridgeway and Ridgeway's mysterious backers would spend the time and money developing a "POTENTIALLY FIRST-IN-CLASS IMMUNE-ONOCOLGY ASSET RT-AR001" only to sell it back to Inspyr. Plus why would Ridgeway etal want 65 million shares, 8000 preferred shares and total control of such a company as Inspyr.
Nice bonus for Colin this yr.. Eiger gets 37.5 million for FDA approval of drug he helped developed Zokinvy (lonafarnib)
Flyersfan.. it now seems that NSPX is all in to the development of the adenosine based drug platform. No mention at all in 10-Q concerning mipsagargin. Nspx could try to sell off rights, patents and IP associated with that platform to generate cash. Some believe that mipsagargin is totally worthless but in bio.. patents, clinical trial results, orphan drug designations are always worth something to some one willing to take a shot and expand the drug therapy. 10-20 mil may be a fair price! Think outside the box!
Don't really know.. I just post info concerning NSPX that I consider relevant. Stopped making corporate financial decisions long ago. One thing that has puzzled me: as you well know Ridgeway was incorporated months after the original agreement with Inspyr. Colin was/is a staff member of Eiger and he started Ridgeway out of his house for the sole purpose to expand the adenosine platform. In a relatively short time Ridgeway has taken the adenosine platform and expanded it into a cutting edge drug therapy that seems to be close to filing a IND. So while working a day job with a side company out of his house he was able to accomplish that feat. Where did that financing come from and who or what entity is actually behind Ridgeway??
It's sooo obvious what has transpired. In 2018 Chris Lowe (previous CEO) with limited medical experience and NSPX out of cash entered an agreement with Colin Hislop (they had previously worked together) to take over the development of the adenosine platform obtained from the merger with L&C. Colin incorporated Ridgeway and thru his well endowed connections researched the adenosine platform and developed the novel drug RT-AR001. Ridgeway then transferred the rights of the adenosine based RT-AR001 back to public company NSPX for 65 mil, perferred stock and total control of NSPX (the existing management led by Michae Cain is not capable to move this forward). It's now Colin's job to get the drug thru the FDA gauntlet of IND, NDA, clinical trials. Good Luck!
Other than the fact there are many bios with no approved drugs and elevated pps and market caps.
NOVEMBER 20, 2020
A big win for COLIN HISLOP and Eiger. " Dr. Hislop was the company's senior medical adviser to the Progeria program and was instrumental to Eiger's first NDA submission of Lonafarnib for the treatment of progeria"
The Progeria Research Foundation and Eiger BioPharmaceuticals Celebrate Historic Milestone with FDA Approval of Zokinvy™ (lonafarnib) for the Treatment of Progeria and Processing-Deficient Progeroid Laminopathies
Colin keeps on getting it done!! NOW HE'S IN COTROL OF ALL IP OF NSPX
Big Pharma controls the marketplace.. most clinical stage bios never get their drugs to market but can license, partner and/or sell off IP if in fact the therapy is deemed worthy. Obviously, it remains to be see what value anything that NSPX owns has commercial value. There are many bios that have no commercial product with market caps of 100 million dollars plus! An example to the extreme Moderna has no approved drugs and the market cap is 36 billion!
Journal of Medicinal Chemistry
November 12, 2020 Issue
Currently, the most promising therapeutic modality for cancer treatment is the blockade of immune checkpoint pathways, which has revolutionized cancer therapy in the past 15 years. Strategies targeting and modulating adenosine A2A receptor (A2AR), an emerging alternative immune checkpoint, have shown the potential to produce significant therapeutic effects.
Colin Hislop, Ridgeway/Inspyr are onto this promising therapy with a novel first in class asset RT-AR001 with a micropartical formulation that may have an effect in treating solid tumors. It's only a matter of time before this therapy gets into clinical trials and beyond.